Focus Partners Advisor Solutions’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Focus Partners Advisor Solutions’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$224K	Buy	+3,001	New	+$221K	﹤0.01%	1242

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $296B AUM 23.14% 1-Year Est. Return

Focus Partners Advisor Solutions's KNSA Position: Q3 2026 in Review

Focus Partners Advisor Solutions opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q3 2026: 3,001 shares worth $224K. The stake represents ﹤0.01% of the portfolio and ranks #1242 among its holdings.

190 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

Focus Partners Advisor Solutions held 3,001 shares of Kiniksa Pharmaceuticals worth $224K as of Q3 2026.
Kiniksa Pharmaceuticals was a new Focus Partners Advisor Solutions position in Q3 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q3 2026, its #1242 holding.
190 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2026, filed 10 Nov 2026.